Nekrasov EV, Perelman JM, Naumov DE et al. A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.12688/f1000research.8084.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water
[version 1; peer review: 2 not approved]
Eduard V. Nekrasov1, Juliy M. Perelman1, Denis E. Naumov1, Anna G. Prikhodko1, Elena V. Ushakova1, Victor P. Kolosov1
Eduard V. Nekrasov1, Juliy M. Perelman1, [...] Denis E. Naumov1, Anna G. Prikhodko1, Elena V. Ushakova1, Victor P. Kolosov1
1Far Eastern Scientific Center of Physiology and Pathology of Respiration, Federal Agency for Scientific Organizations, Blagoveshchensk, Russian Federation
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
This study aims at identifying prostaglandin D2 (PGD2) involvement in osmotic airway hyperresponsiveness of asthmatics. PGD2 primary plasma metabolite, 11β-PGF2α, was analyzed in exhaled breath condensate (EBC) in response to ultrasonically nebulized distilled water (UNDW) and in serum in asthmatics with different airway response to the hypoosmotic stimulus. The total group of asthmatics (n=27) had a lower basal level of 11β-PGF2α (0.38±0.13 pg/ml, mean±SEM) in EBC compared to a group of healthy subjects (0.86±0.31 pg/ml, n=5), which decreased following the UNDW challenge to 0.30±0.09 and 0.53±0.12, respectively. The group of asthmatics with airway hyperresponsiveness to UNDW (≥10% FEV1 drop from baseline, n=14) had a lower concentration of the metabolite (0.28±0.14 pg/ml) as compared to the group without hyperresponsiveness (0.49±0.31 pg/ml, n=10). The 11β-PGF2α concentration decreased in the both groups after the challenge: 0.20±0.04 and 0.23±0.07 pg/ml in the groups with and without hyperresponsiveness to UNDW, respectively . Serum content of 11β-PGF2α was ranging from 0 to 61 pg/ml in asthmatics (n=17) and from 7.3 to 85.4 pg/ml in healthy subjects (n=8). It was lower in the group with airway hyperresponsiveness to UNDW (8.4±1.7 pg/ml, n=9) than in the group without the hyperresponsiveness (21.0±8.8 pg/ml, n=8). The obtained results do not support the involvement of PGD2 in the pathophysiology of asthma with airway hyperresponsiveness to a hypoosmotic stimulus unless other conversions of the prostaglandin occur in the airway under these conditions with formation of metabolites different from 11β-PGF2α.
Corresponding author:
Eduard V. Nekrasov
Competing interests:
No competing interests were disclosed.
Grant information:
The research was supported by Russian Scientific Foundation (grant No.14-25-00019 was awarded to the Far Eastern Scientific Center of Physiology and Pathology of Respiration, the leader of the project is Dr. J.M. Perelman).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Prostaglandin D2 (PGD2) is produced by mast cells and macrophages increasing in response to allergen exposure. In asthmatics, PGD2 affects the airways by causing bronchoconstriction, vasodilation, increasing capillary permeability and mucous production1. The role of the prostaglandin in asthmatics with osmotic airway hyperresponsiveness is ill-defined. PGD2 is an unstable compound rapidly metabolized with 11β-PGF2α being its primary plasma metabolite. The aim of this study was estimation of 11β-PGF2α in exhaled breath condensate (EBC) in response to ultrasonically nebulized distilled water (UNDW) and serum in asthmatics with different airway response to the hypoosmotic stimulus.
Methods
The study protocol was approved by the Biomedical Ethics Committee of the Far Eastern Scientific Center of Physiology and Pathology of Respiration (permit #91-1 of 12.01.2015). 39 patients with mild to moderate asthma and 13 healthy subjects participated in the study. The patients were recruited from the Center’s in-patient facilities or invited for follow-up checks. EBC was collected from 27 asthmatics and 5 healthy subjects before and after 3 min provocation with UNDW. Aerosol (the particle size range 0.5–10 μm, average particle size 3 μm) was generated by a Thomex L-2 ultrasonic nebulizer (Poland) operated at 4.5 ml/min. The hypoosmolar challenge test consisted of two consecutive inhalations for 3 min each. The first inhalation was with 30 ml of isotonic solution (0.9% NaCl), and the second with the same volume of distilled water. The temperature of the solution was maintained at 37.3°C. During the inhalation, a participant used a nose-clip and was breathing in a calm manner through a mouthpiece connected via a two-way valve to the container with a solution. Lung function testing was conducted with a spirometer Easy on-PC (ndd Medizintechnik AG, Switzerland) before the provocation test (baseline) and at 1 and 5 min of the recovery period. A drop in forced expiratory volume in 1 sec (ΔFEV1) of 10% or more from baseline after inhalation with UNDW was considered as airway hyperresponsiveness to the hypoosmotic stimulus. Patients who experienced airway responsiveness to isotonic solutions (n=3) were excluded from the test with UNDW, and they were not included in any group except the total group of asthmatics. Patients who experienced any airway responsiveness were given 2 doses of a selective β2-adrenoceptor agonist to prevent bronchoconstriction. EBC was collected during tidal breathing with a condensing device ECoScreen 2 (Erich Jaeger, Germany). Serum was obtained from 17 patients and 8 healthy subjects before the provocation test. The collected samples were stored at -70°C until analysis. The concentration of 11β-PGF2α was measured by 11β-prostaglandin F2α EIA kit (No. 516521, Cayman Chemical Company, USA) in EBC after freeze-drying and in serum after purification by solid phase extraction on C18 cartridges (Strata C18-E, 55 μm, 70A, 500 mg/6 ml, Phenomenex, USA) as recommended by the manufacturer [Cayman’s kit booklet. URL: https://www.caymanchem.com/pdfs/516521.pdf]. The EIA kit utilizes 11β-PGF2α-specific rabbit antiserum, and mouse anti-rabbit monoclonal antibody. Each sample was assayed in duplicate. The optical densities of the samples were used to calculate the concentrations of 11β-PGF2α using an automated Excel spreadsheet [A. Swart 2012–2015. URL: http://www.rheumatologie-neuss.net/index_files/RheumatologieNeuss13.htm].
Analysis of the data was performed using standard methods of variational statistics. Statistical differences between groups were calculated by Student’s t test or by the nonparametric criteria of Mann-Whitney and Kolmogorov-Smirnov tests in the case of non-Gaussian distribution of variables (Statistica 8.0, StatSoft Inc., Tulsa, OK, USA, 2008).
Results
Standard pg/ml
%B/B0
0
100
0.256
90.6
0.64
75.8
1.6
71.3
4.1
69
10.2
53.3
Dataset 1.Data for calibration curves.
Standard Bound/Maximum Bound (%B/B0) values were obtained for the concentrations of the standard (11β-PGF2α, pg/ml) which were used to build calibration curves for calculations of 11β-PGF2α content in EBC (Table 1) and serum (Table 2) samples. The values were produced with different EIA kits on different days.
Group of subjects and EBC sample #
Provocation with UNDW
11?-PGF2? pg/ml
%?FEV1 from baseline
Note
Subjects with asthma
24
Before
0.332
N.D.
Reaction to 0.9% NaCl
After
0.403
31
Before
0.488
-15
After
0.232
34
Before
1.063
N.D.
Reaction to 0.9% NaCl
After
2.323
40
Before
0.55
-10
After
0.251
44
Before
0.341
-2.8
After
0.649
45
Before
0.609
-3.1
After
0.446
47
Before
0
-7.4
After
0.079
50
Before
0.527
1.5
After
0.258
56
Before
0.246
-43
After
0.241
60
Before
3.092
-7.1
After
0.302
73
Before
0.08
-3.7
After
0.085
76
Before
0.041
-9.7
After
0.311
78
Before
0.096
-10
After
0.06
80
Before
0.107
-3.2
After
0.066
81
Before
0.02
3.8
After
0.082
82
Before
0.084
N.D.
Reaction to 0.9% NaCl
After
0.162
83
Before
0.15
-45
After
0.157
84
Before
0.047
1.9
After
0.054
87
Before
0.036
-10
After
0.042
89
Before
0.125
-11
After
0.284
98
Before
0.052
-27
After
0.079
99
Before
0.007
-74
After
0.367
100
Before
1.875
-13
After
0.388
102
Before
0.081
-42
After
0.04
108
Before
0.101
-24
After
0.059
112
Before
0.031
-15
After
0.179
120
Before
0.128
-26
After
0.466
Healthy subjects
109
Before
0.447
N.D.
After
0.589
113
Before
0.557
N.D.
After
0.557
115
Before
0.323
N.D.
After
0.205
118
Before
1.196
N.D.
After
0.472
127
Before
1.776
N.D.
Dataset 2.11β-PGF2α content (pg/ml) in exhaled breath condensate (EBC) of individual subjects before and after provocation with ultrasonically nebulized distilled water and change in forced expiratory volume in 1 sec (% ΔFEV1 from baseline) after the provocation.
N.D. – not determined; UNDW - ultrasonically nebulized distilled water.Note: Patients who had reaction to 0.9% NaCl were excluded from the test with ultrasonically nebulized distilled water.
Group of subjects and serum sample #
11?-PGF2? pg/ml
%?FEV1 from baseline
Subjects with asthma
73
8.1
-3.7
80
5.8
-45
81
55.8
1.9
137
17.1
-11
146
4.8
-15
82
11.8
15.8
87
11.9
-5.6
89
9.4
-6.8
97
4.4
1.3
99
7.5
-14.1
100
12.8
-21
102
61.1
-2
103
10
-19
104
7.2
-19
127
5.6
2.4
130
10.4
-25
131
0
-11
Healthy subjects
98
7.3
N.D.
108
9.4
N.D.
109
22.2
N.D.
112
24.3
N.D.
113
85.4
N.D.
115
16.3
N.D.
118
83.4
N.D.
Dataset 3.11β-PGF2α content (pg/ml) in serum of individual subjects before provocation with ultrasonically nebulized distilled water and change in forced expiratory volume in 1 sec (% ΔFEV1 from baseline) after the provocation (if applicable).
N.D. – not determined
The level of 11β-PGF2α in EBC was below the announced detection limit (80% B/B0) of the kit (5.5 pg/ml). For the estimation of the 11β-PGF2α level in EBC before and after the provocation test and comparison of the changes in the groups of healthy subjects and asthmatics with and without airway hyperresponsiveness to UNDW, calibration curves were built using the 11β-PGF2α standard in the range of 0–25.6 pg/ml with additional dilutions of the standard down to 0.64 and 0.256 pg/ml and plotting %B/B0 vs. 11β-PGF2α concentration. Obtained values of %B/B0 for the dilutions were different from 100% (Dataset 1, Table 1).
Table 1. 11β-PGF2α content (pg/ml) in EBC and serum of subjects with different responsiveness to UNDW (values indicate number of subjects, n, range/mean±SEM).
Asthmatics, total group
Asthmatics with AHR to UNDW
Asthmatics without AHR to UNDW
Healthy subjects
EBC
Before provocation
n=27 0.00–3.09/0.38±0.13
n=14 0.01–1.88/0.28±0.14
n=10 0.00–3.09/0.49±0.31
n=5 0.32–1.79/0.86±0.31
After provocation
n=27 0.04–2.32/0.30±0.09
n=14 0.04–0.47/0.20±0.04
n=10 0.05–0.65/0.23±0.07
n=5 0.21–0.85/0.53±0.12
Serum
Before provocation
n=17 0.0–61.1/14.3±4.3
n=9 0.0–17.1/8.4±1.7
n=8 4.4–61.1/21.0±8.8
n=8 7.3–85.4/33.7±12.1
Abbreviations: AHR – airway hyperresponsiveness; EBC – exhaled breath condensate; SEM – standard error of mean; UNDW – ultrasonically nebulized distilled water
As a result, the calculated content of 11β-PGF2α in EBC was in the range of 0–3.1 pg/ml (Table 1). The total group of asthmatics had a lower basal level of 11β-PGF2α (0.38±0.13 pg/ml, mean±SEM) compared to the group of healthy controls (0.86±0.31 pg/ml), which further decreased following the UNDW challenge to 0.30±0.09 and 0.53±0.12, respectively. The group of asthmatics with airway hyperresponsiveness to UNDW was found to have a lower concentration of the metabolite (0.28±0.14 pg/ml) as compared to the group without the hyperresponsiveness (0.49±0.31 pg/ml). The 11β-PGF2α concentration decreased in both groups after the challenge: 0.20±0.04 and 0.23±0.07 pg/ml in the groups with and without hyperresponsiveness to UNDW, respectively.
The content of 11β-PGF2α in serum was higher ranging from 0 to 61 pg/ml in the total group of asthmatics and from 7.3 to 85.4 in healthy subjects (Table 1). Once again, it was lower on average in the total group of asthmatics than in the healthy subjects (14.3±4.3 vs. 33.7±12.1 pg/ml), and lower in the group with airway hyperresponsiveness to UNDW (8.4±1.7 pg/ml) than in the group without hyperresponsiveness (21.0±8.8 pg/ml). Due to the high variation of 11β-PGF2α content in the subjects, all differences were statistically insignificant (p>0.05).
Since prostaglandin D2 is considered to be a mast cell- and macrophage-specific eicosanoid, the lack of an increase in the concentration of its major metabolite 11β-PGF2α found in the present study suggests a diminished role of these immune cells in the pathogenesis of the inflammatory reaction in asthma patients with osmotic airway hyperresponsiveness. However, the formation of different metabolites of PGD2, apart from 11β-PGF2α, have been reported2 which may possess different physiological activities.
Conclusion
The obtained results do not support the involvement of PGD2 in the pathophysiology of asthma with airway hyperresponsiveness to a hypoosmotic stimulus unless other conversions of the prostaglandin occur in the airway under these conditions with formation of metabolites different from 11β-PGF2α. It would be interesting to investigate the level of other possible metabolites of PGD2.
F1000Research: Dataset 2. 11β-PGF2α content (pg/ml) in exhaled breath condensate (EBC) of individual subjects before and after provocation with ultrasonically nebulized distilled water and change in forced expiratory volume in 1 sec (% ΔFEV1 from baseline) after the provocation, 10.5256/f1000research.8084.d1154184
F1000Research: Dataset 3. 11β-PGF2α content (pg/ml) in serum of individual subjects before provocation with ultrasonically nebulized distilled water and change in forced expiratory volume in 1 sec (% ΔFEV1 from baseline) after the provocation (if applicable), 10.5256/f1000research.8084.d1154195
Consent
The study protocol was approved by the Biomedical Ethics Committee of the Far Eastern Scientific Center of Physiology and Pathology of Respiration (permit #91-1 of 12.01.2015), and the participants gave written informed consent.
Author contributions
AGP – design of the protocol, the recruitment and clinical investigation of the subjects, data collection and analysis, approval of the manuscript. DEN and EVU – method development, data acquisition, approval of the manuscript. EVN – sample processing (lyophilisation, purification by SPE), data analysis, drafting of the manuscript. JMP – leader of the project, conception and design of the study, critical revision of the manuscript, final approval of the version. VPK – conception of the study, final approval of the manuscript.
Competing interests
No competing interests were disclosed.
Grant information
The research was supported by Russian Scientific Foundation (grant No.14-25-00019 was awarded to the Far Eastern Scientific Center of Physiology and Pathology of Respiration, the leader of the project is Dr. J.M. Perelman).
I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgement
The authors are thankful to Galina A. Makarova (FESC PPR) for technical assistance.
F1000 recommended
References
1.
Oguma T, Asano K, Ishizaka A:
Role of prostaglandin D2 and its receptors in the pathophysiology of asthma.
Allergol Int.
2008; 57(4): 307–312. PubMed Abstract
| Publisher Full Text
2.
Schuligoi R, Schmidt R, Geisslinger G, et al.:
PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors.
Biochem Pharmacol.
2007; 74(1): 107–117. PubMed Abstract
| Publisher Full Text
3.
Nekrasov EV, Perelman JM, Naumov DE, et al.:
Dataset 1 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water.
F1000Research.
2016. Data Source
4.
Nekrasov EV, Perelman JM, Naumov DE, et al.:
Dataset 2 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water.
F1000Research.
2016. Data Source
5.
Nekrasov EV, Perelman JM, Naumov DE, et al.:
Dataset 3 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water.
F1000Research.
2016. Data Source
1
Far Eastern Scientific Center of Physiology and Pathology of Respiration, Federal Agency for Scientific Organizations, Blagoveshchensk, Russian Federation
The research was supported by Russian Scientific Foundation (grant No.14-25-00019 was awarded to the Far Eastern Scientific Center of Physiology and Pathology of Respiration, the leader of the project is Dr. J.M. Perelman).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Nekrasov EV, Perelman JM, Naumov DE et al. A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.12688/f1000research.8084.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Santini G. Reviewer Report For: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8696.r20065)
The critical point of this article is the detection limit of the ELISA KIT used. The concentration of metabolite measured in EBC was too much low. I suggest to concentrate the sample by evaporation under vacuum, or use an another
... Continue reading
The critical point of this article is the detection limit of the ELISA KIT used. The concentration of metabolite measured in EBC was too much low. I suggest to concentrate the sample by evaporation under vacuum, or use an another KIT with a higher sensitivity.
The number of healthy subjects from which it was collected EBC is too low. I suggest of collect others EBC samples from healthy subjects.
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.
Santini G. Reviewer Report For: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8696.r20065)
Bikov A. Reviewer Report For: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8696.r17321)
I read the article with great interest. Lipid metabolites play a role in the pathophysiology of asthma and their changes during different stimuli are of interest.
The critical point of the article is that the EBC
... Continue reading
I read the article with great interest. Lipid metabolites play a role in the pathophysiology of asthma and their changes during different stimuli are of interest.
The critical point of the article is that the EBC 11β-PGF2α levels were below the lower detection limit of the ELISA kit used in the study. Thus, the authors can simply not conclude on the results as they might have experienced changes and differences on variations of zero (distilled water)... To resolve this crucial error, I recommend concentrating the sample (i.e. vacuum evaporation), or adding a known concentration of standard to each sample to overcome the detection limit.
The article is too short. Methodology of EBC collection is extremely variable, and to compare results with external findings, EBC methodology needs to be decribed in more detail.
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.
Bikov A. Reviewer Report For: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water [version 1; peer review: 2 not approved]. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8696.r17321)
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
How to fix it
Save downloaded CSV file
Open spreadsheet program (e.g. Excel)
Click the ‘Data’ tab at the top
Click the ‘From text’ icon (top left)
Browse for downloaded CSV file, click ‘Import’
Ensure ‘Delimited’ radio button is selected, click ‘Next’
Check one of the appropriate delimiter checkboxes (you can visualize the formatting by looking at the data preview below these options)
Nekrasov EV, Perelman JM, Naumov DE et al.. Dataset 1 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8084.d115417)
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
How to fix it
Save downloaded CSV file
Open spreadsheet program (e.g. Excel)
Click the ‘Data’ tab at the top
Click the ‘From text’ icon (top left)
Browse for downloaded CSV file, click ‘Import’
Ensure ‘Delimited’ radio button is selected, click ‘Next’
Check one of the appropriate delimiter checkboxes (you can visualize the formatting by looking at the data preview below these options)
Nekrasov EV, Perelman JM, Naumov DE et al.. Dataset 2 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8084.d115418)
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
How to fix it
Save downloaded CSV file
Open spreadsheet program (e.g. Excel)
Click the ‘Data’ tab at the top
Click the ‘From text’ icon (top left)
Browse for downloaded CSV file, click ‘Import’
Ensure ‘Delimited’ radio button is selected, click ‘Next’
Check one of the appropriate delimiter checkboxes (you can visualize the formatting by looking at the data preview below these options)
Nekrasov EV, Perelman JM, Naumov DE et al.. Dataset 3 in: A metabolite of prostaglandin D2, 11β-prostaglandin F2α (11β-PGF2α), in exhaled breath condensate and serum of asthmatics with airway hyperresponsiveness to distilled water. F1000Research 2016, 5:307 (https://doi.org/10.5256/f1000research.8084.d115419)
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)